Press release
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex
About this update from Royalty Pharma Plc
[{"type":"text","content":"NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million.\n Pablo Legorreta, Royalty Pharma’s Founder and Chief Executive Officer, stated, “We are excited to build on our long-standing relationship with the CF Foundation. Our initial landmark funding transaction in 2014 enabled the Foundation to expand its efforts to develop new lifesaving therapies and improve care for patients, and exemplified our leadership role as an innovator in funding the biopharma ecosystem. We are similarly optimistic that today’s transaction will further support the CF Foundation’s work to fund research and drug development and advance high-quality, specialized CF care.” As part of previous agreements with the CF Foundation, Royalty Pharma purchased all of the CF Foundation’s royalty interests on Vertex’s CF franchise. Under the terms of those agreements, Royalty Pharma was obligated to pay the CF Foundation 50% of royalties attributable to revenue over $5.8 billion in any calendar year. Today’s agreement eliminates this obligation and entitles Royalty Pharma to all royalties above the previous revenue threshold. The Vertex CF franchise generated net revenues totalling over $4.0 billion in 2019. The royalties under this agreement are perpetual and not tied to patent expirations. Relative to Royalty Pharma’s existing business, this transaction is expected to enhance the company’s long-term Adjusted Cash Receipts and Adjusted Cash Flow growth. MTS Health Partners and Mintz Levin acted as advisors to the Cystic Fibrosis Foundation on the transaction and Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties whic...